Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986326 in moderate-to-severe atopic dermatitis
NCT06248814Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2024
- Primary completion
- Nov 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of BMS-986326 in atopic dermatitis (AD) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events at 224 days, Serious Adverse Events at 224 days and 4 more. Started Mar 2024; status: completed.
02
Drugs
BMS-986326
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06248814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248814.